ADMA Biologics (NASDAQ:ADMA) Announces Earnings Results, Hits Estimates

ADMA Biologics (NASDAQ:ADMA) announced its quarterly earnings data on Wednesday. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16, FiscalAI reports. The business had revenue of $124.39 million for the quarter, compared to analysts’ expectations of $125.34 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%.

ADMA Biologics Price Performance

ADMA Biologics stock traded up $0.35 during mid-day trading on Wednesday, hitting $9.26. 3,751,122 shares of the company traded hands, compared to its average volume of 4,666,846. ADMA Biologics has a one year low of $7.21 and a one year high of $20.46. The stock has a fifty day moving average price of $8.52 and a 200-day moving average price of $11.43. The stock has a market cap of $2.15 billion, a price-to-earnings ratio of 13.62 and a beta of 0.74. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.93 and a current ratio of 6.95.

ADMA Biologics News Summary

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: An earnings preview highlighted potential valuation upside, with GF Value estimating substantial appreciation if ADMA’s operating performance meets expectations. Investors may also be positioning ahead of the company’s second-quarter 2026 results. Earnings To Watch: ADMA Biologics Inc Q2 2026
• Neutral Sentiment: Multiple law firms reiterated an August 10 deadline for investors to seek lead-plaintiff status in a securities class action covering purchases made from August 9, 2024, through March 25, 2026. These announcements largely repeat previously reported litigation rather than represent a new operating development. Robbins LLP ADMA investor deadline notice
• Negative Sentiment: ADMA faces mounting legal and governance scrutiny. The lawsuits allege that the company and certain executives misrepresented its financial condition, revenue recognition, inventory distribution and business practices, following a reported 29% share-price decline tied to Culper Research allegations of channel stuffing. Kehoe Law Firm is separately investigating whether officers and directors breached fiduciary duties or failed to properly oversee the company. The allegations have not been proven, but potential litigation costs, damages, disclosure concerns and reputational harm could pressure the stock. Kehoe Law Firm ADMA shareholder alert ADMA channel stuffing allegations and class action

Insider Activity

In other ADMA Biologics news, Director Jerrold B. Grossman acquired 12,500 shares of the stock in a transaction dated Monday, May 11th. The stock was purchased at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the acquisition, the director owned 513,884 shares in the company, valued at $4,116,210.84. The trade was a 2.49% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 3.90% of the company’s stock.

Hedge Funds Weigh In On ADMA Biologics

A number of hedge funds have recently bought and sold shares of the business. State Street Corp grew its stake in ADMA Biologics by 0.3% during the fourth quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock valued at $248,014,000 after acquiring an additional 35,614 shares in the last quarter. Nuveen LLC increased its stake in ADMA Biologics by 3.5% during the fourth quarter. Nuveen LLC now owns 5,926,390 shares of the biotechnology company’s stock worth $108,097,000 after acquiring an additional 202,245 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in ADMA Biologics by 0.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,835,638 shares of the biotechnology company’s stock valued at $88,204,000 after purchasing an additional 37,364 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of ADMA Biologics by 3,906.1% in the 4th quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company’s stock valued at $71,820,000 after buying an additional 3,838,158 shares during the period. Finally, Caligan Partners LP raised its position in shares of ADMA Biologics by 14.3% during the 4th quarter. Caligan Partners LP now owns 3,012,508 shares of the biotechnology company’s stock worth $54,948,000 after purchasing an additional 375,899 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Raymond James Financial started coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 price target on the stock. Wall Street Zen cut shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Mizuho lowered their target price on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a report on Thursday, June 18th. Finally, Zacks Research upgraded shares of ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $18.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.